Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Teniposide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | TOP2B known ✓ | Q02880 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | GAA | P10253 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teniposide SCHEMBL6027493 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Teniposide SCHEMBL14008692 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Teniposide SCHEMBL9607866 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Teniposide SCHEMBL5968656 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Teniposide SCHEMBL14031677 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Teniposide SCHEMBL23202938 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Teniposide SCHEMBL12278906 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Teniposide SCHEMBL13809319 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Teniposide SCHEMBL13712547 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Teniposide SCHEMBL12279643 | 1.00 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894960-B2 | Compositions and methods for nucleic acid transfer | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20190133985-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | Orbus Therapeutics, Inc. | 2019-05-09 | — | — | US | disclosed |
| US-20180057813-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID TRANSFER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-01 | — | — | US | disclosed |
| US-20180057813-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID TRANSFER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-01 | — | — | US | disclosed |
| US-20150168424-A1 | IGFBP2 Biomarker | WANG YAN (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150168424-A1 | IGFBP2 Biomarker | WANG YAN (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20110014117-A1 | ANTI-IGF1R | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110014117-A1 | ANTI-IGF1R | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
| US-20100143340-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| CN-101292957-A | Liposome preparation of teniposide phospholipid complexes and prepraring method thereof | UNIV PLA 2ND MILITARY MEDICAL (CN) | 2008-10-29 | — | — | CN | disclosed |
| US-20080112888-A1 | IGFBP2 BIOMARKER | SCHERING CORPORATION | 2008-05-15 | — | — | US | disclosed |
| US-20080112888-A1 | IGFBP2 BIOMARKER | SCHERING CORPORATION | 2008-05-15 | — | — | US | disclosed |
| US-20080090242-A1 | PANEL OF BIOMARKERS FOR PREDICTION OF FTI EFFICACY | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080090242-A1 | PANEL OF BIOMARKERS FOR PREDICTION OF FTI EFFICACY | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150168424-A1 | IGFBP2 Biomarker | IGFBP2, IGFBP1, IGFBP5 | TOP2A 1747/4885TOP2B 2405/4885CYP3A4 3596/4885 |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | IGF1R, IRS1, EWSR1 | TOP2A 3462/4885TOP2B 4058/4885CYP3A4 2778/4885 |
| US-20080112888-A1 | IGFBP2 BIOMARKER | IGFBP2, IGFBP1, IGFBP5 | TOP2A 1747/4885TOP2B 2405/4885CYP3A4 3596/4885 |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | TOP2A 395/4885TOP2B 211/4885CYP3A4 2149/4885 |
| US-20110014117-A1 | ANTI-IGF1R | IGF1R, IGFBP1, IGFBP2 | TOP2A 1919/4885TOP2B 2090/4885CYP3A4 4884/4885 |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | TERF2IP, TERF2, DOT1L | TOP2A 75/4885TOP2B 197/4885CYP3A4 4781/4885 |
| US-10894960-B2 | Compositions and methods for nucleic acid transfer | SNRPE, RNASE1, POLRMT | TOP2A 457/4885TOP2B 467/4885CYP3A4 4885/4885 |
| US-20100143340-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, KLK3, CD44 | TOP2A 249/4885TOP2B 356/4885CYP3A4 4658/4885 |
| US-20190133985-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | AHCY, SRM, MAT2A | TOP2A 1923/4885TOP2B 2698/4885CYP3A4 4297/4885 |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | BRCA1, VHL, TP53 | TOP2A 155/4885TOP2B 149/4885CYP3A4 3752/4885 |
| US-20180057813-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID TRANSFER | SNRPE, RNASE1, POLRMT | TOP2A 457/4885TOP2B 467/4885CYP3A4 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.